user-avatar
SMH.com.au

Melanoma mRNA treatment set to cut recurrence by 42 per cent in worldfirst

The world’s first major trial of a personalised therapeutic cancer vaccine has been hailed a ‘foundational shift’ in how we research and treat cancer.